Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage trial met its main goal.

In this regard Novo Nordisk is leading the way. We've become increasingly committed to chronic conditions that include cardiovascular disease and chronic kidney disease – the reason being ...

Novo Nordisk jumps 5% as Parvus Asset Management builds a stake to sway CEO succession amid leadership shakeup and pipeline ...

Novo Nordisk (NVO) said its popular diabetes ... and death from cardiovascular disease in adults with type 2 diabetes and chronic kidney disease. The Danish drugmaker said the approval makes ...

Novo Nordisk is pursuing new indications for semaglutide, including label expansions for Wegovy in additional cardiovascular conditions and for Ozempic in T2D patients with chronic kidney disease.

Novo Nordisk NVO shares have gained 5.8% in a week. The uptrend in the stock price was driven by reports of an activist hedge ...

A spirited pro/con debate at ERA 2025 explores whether population-level albuminuria screening could improve early CKD ...

A protocol designed for primary care increased weight loss across a quarter of a million people, but only 25% of those with a ...

GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.

The first diabetes and obesity pill that is similar to Ozempic — but in tablet form — may actually outperform the popular ...

An international clinical trial, led in the UK by Swansea’s Joint Clinical Research Facility (JCRF), has found that ...